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Purpose: In the United States, lung cancer represents the third most
common cancer, causing the most cancer-related deaths, with treat-
ment advances minimally affecting 5-year survivals. Erb-B family
receptor elevations are found in many non-small cell lung cancer
tumors, making this receptor family a drug target with potential for
improving survival.
Design: Chemotherapy-naive patients with advanced non-small cell
lung cancer were enrolled who had at least one elevated tumor-
expressed member of the erb-B family receptors. This dose-finding,
multicenter, open-label, phase I study combined chemotherapy with
paclitaxel and carboplatin, adding the tyrosine kinase inhibitor
CI-1033. Patients were evaluated for toxicity, response, survival,
and pharmacokinetics.
Results: All 39 patients enrolled were assessable for safety and
efficacy. Dose-limiting toxicities (diarrhea, rash, asthenia, and hy-
potension) occurred at the 200- and 150-mg dose levels of CI-1033;
the maximum tolerated dose was 100 mg. Most toxicities were mild
to moderate. Pharmacokinetics studies showed that paclitaxel levels
were unaffected by CI-1033 and that CI-1033 plasma concentrations
were consistent with historical controls. Ten patients (25.6%)
achieved partial responses and another 11 (28.2%) had stable dis-
ease. In the recommended phase II dose cohort (n 23), six patients
(26%) had partial responses and six (26%) had stable disease.
Median survival time was 12.4 months; median progression-free
survival was 5.1 months.
Conclusion: Paclitaxel-carboplatin, combined with CI-1033 at 100
mg/day, was safe and well tolerated. Efficacy and survival results
were comparable to those of similar studies in advanced non-small
cell lung cancer and therefore warrant additional phase II testing.
Key Words: Non-small cell lung cancer, Chemotherapy, Tyrosine
kinase.
(J Thorac Oncol. 2006;1: 1010–1019)
In the United States, lung cancer represents the third mostcommon cancer, yet it is responsible for the most cancer-
related deaths.1 Advances in the treatment of lung cancer
have been sporadic and small, and the overall 5-year survival
remains at only 15%.1 However, lung cancer incidence and
mortality continue to decrease in men and have begun to
stabilize in women1; decreases in incidence and mortality
have been observed with smoking prevention strategies,2 and
therapeutic improvements have been reported in all stages of
the disease.3,4 Furthermore, the recognition of multiple sig-
naling pathways involved in malignant transformation and
tumor progression5 have identified several targets against
which to develop new drugs6,7 and a series of biomarkers that
present new challenges but provide greater opportunities to
the design and analysis of future translational and clinical
research.8
Among these targets, one of the most widely studied is
epidermal growth factor receptor (EGFR), a member of the
erb-B tyrosine kinase (TK) receptor family (erb-B 1, 2, 3, and
4 or EGFR, HER-2/neu, HER-3, and HER-4).9 Activation of
this receptor (homo- or heterodimerization) leads to auto-
phosphorylation of tyrosine residues in the intracellular do-
main, which then triggers downstream signaling through
various pathways, including MAPK, PI3K/Akt, and STAT.10
This ultimately results in cell proliferation, angiogenesis,
invasion and metastasis, and inhibition of apoptosis.10,11
In non-small cell lung cancer (NSCLC), expression of
EFGR by immunohistochemistry (IHC) has been reported in
50% to 90% of cases, with overexpression present in as many
as 50% of cases.9,10 There is also evidence of EGFR gene
amplification, and, recently, activating mutations in the
EGFR adenosine triphosphate–binding site have been discov-
ered.12 Although in some studies, EGFR overexpression may
be correlated with poor prognosis and chemotherapy resis-
tance,13 mutations (considered a predictive and prognostic
factor) render the malignant cells exquisitely sensitive to TK
inhibitors (TKIs) such as gefitinib and erlotinib14 and poten-
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tially also to other TKIs under development. The clinical
roles of mutations, gene amplification, and EGFR overex-
pression are still under investigation.
EGFR TKIs have failed to improve survival when
evaluated in combination with first-line chemotherapy.15,16
As second- or third-line therapy, single-agent erlotinib17
showed improved survival and quality of life over best
supportive care, although gefitinib18 failed to do so (results
approached statistical significance). However, patients with
cancers containing mutations of EGFR appear to be particu-
larly sensitive to EGFR TKIs. It is unclear why studies of
erlotinib have shown benefit, whereas gefitinib failed to show
improved survival. It is possible that there are intrinsic
differences between these two drugs. However, the results to
date emphasize the importance of rigorous laboratory and
translational testing in earlier trials to assess newer agents
with “similar” mechanisms of action but “different” pharma-
cologic properties.
CI-1033 is an oral, highly potent dihydrochloride 4-ani-
linoquinazoline TKI that covalently binds to cysteine residues
in the ATP binding pocket of all erb-B receptor family
members (pan–erb-B inhibitor), resulting in their irreversible
inactivation.19 Preclinically, CI-1033 has shown complete
inhibition of EGFR autophosphorylation in vitro and in vivo.
Oral CI-1033 significantly delayed the growth of several
human xenografts in mice (including H125 NSCLC).20 Fur-
thermore, A431 human tumor xenograft models with CI-1033
in combination with paclitaxel have shown that treatment
with paclitaxel first followed 1 day later with CI-1033 was a
highly efficacious schedule in which the combination pro-
duced a greater therapeutic effect than either drug alone.21
This schedule-dependent additive effect (occurring only
when CI-1033 is given a day after chemotherapy) has also
been demonstrated with gemcitabine, suggesting that CI-1033
interferes with anticancer activity, by inducing cell cycle arrest,
when given before or at the same time of chemotherapy.22
Clinically, CI-1033 was evaluated in three phase I dose
escalation studies in which patients were dosed once daily for
7 days every 21 days, once weekly for 3 weeks every 4
weeks, or once daily for 14, 21, or 28 days followed by a
7-day drug holiday. The plasma elimination half-life for
CI-1033 was calculated at 5.3 hours, and CI-1033 did not
accumulate with repeated dosing under any regimen. Addi-
tionally, single-agent CI-1033 was generally well tolerated
with the most common adverse events (AEs) predominantly
being grade 1 or 2 in severity and including diarrhea (30%–
50%), rash (20%–50%), and nausea/vomiting (20%–45%).23–25
Based on these studies and the single-agent efficacy and
safety of CI-1033, this phase I clinical trial was launched in
chemotherapy-naive patients with advanced NSCLC. CI-
1033 scheduling was different from that of other EGFR TKIs.
It was given on days 2 to 14 to avoid overlap with initial
chemotherapy and allow for washout before subsequent che-
motherapy (schedule-dependent additive effect) and know-
ing that pharmacodynamics activity with daily CI-1033
persisted (suppression of EGFR phosphorylation in tumor
tissue continued 1 week after therapy) despite weekly drug
rest periods.26
PATIENTS AND METHODS
Study Population and Patient Eligibility
Patients were required to have histologic disease con-
firmation, estimated life expectancy of 12 weeks, Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) 1 determined within 2 weeks before therapy start, at
least one unidimensionally measurable lesion, and a tumor
specimen with at least 10% staining at an intensity 2 for
erb-B 1, 2, 3, or 4 as assessed by IHC. Other eligibility
criteria included age 18 years and older, no previous chemo-
therapy or biologic or immunotherapy, and adequate bone
marrow (absolute neutrophil count [ANC] 2.0  109 cells/
liter, platelet count 100  109 cells/liter), renal (calculated
or measured creatinine clearance 60 ml/min), and hepatic
functions (bilirubin 1.5 upper limit of normal [ULN], ala-
nine aminotransferase and/or aspartate aminotransferase
2.5 ULN or5 ULN with documented liver metastasis).
Tumor biopsy material was collected either as paraffin-
embedded blocks or unstained slides for IHC quantitative
determination of all the erb-B receptor family members.
Patients with brain metastasis or previous definitive
radiation therapy to the primary site as well as women who
were pregnant, nursing, or of childbearing potential (not
using adequate methods of birth control) were excluded from
the study. Written informed consent was obtained from each
subject and an institutional review board reviewed and ap-
proved the study protocol at each institution.
Study Design
This was an open-label, noncomparative, dose-finding,
multicenter phase I study. Five centers in North America
(University of Texas M. D. Anderson Cancer Center, H. Lee
Moffitt Cancer Center and Research Institute, Louisville
Oncology, Lutheran General Cancer Care Center, and Ju-
ravinski Cancer Centre) participated. The primary objective
was to determine the dose-limiting toxicities (DLTs) and
maximum tolerated dose (MTD) of CI-1033, given daily for
14 days (days 2–15) in combination with commonly used
doses of paclitaxel-carboplatin (day 1). Secondary objectives
included (1) defining the recommended phase II dose (RP2D)
and safety profile of the combination; (2) evaluating pharma-
cokinetics (pK) interactions between CI-1033 and paclitaxel-
carboplatin, (3) determining the safety profile of maintenance
single-agent CI-1033, and (4) determining the regimen’s
antitumor activity by measuring the overall response rate
(ORR), progression-free survival (PFS), and overall survival
(OS).
DLT was defined as an AE thought to be related to
treatment with paclitaxel-carboplatin and CI-1033 that satis-
fied the following criteria:
Y Grade 4 neutropenia (ANC0.5 109/liter) lasting7
days;
Y Platelets 20  109/liter;
Y Grade 3 prothrombin time and/or activated partial
thromboplastin time in the absence of anticoagulant
therapy;
Y Any other grade 4 hematologic toxicity, including co-
agulopathy in the absence of anticoagulant therapy;
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Y Any grade 3 nonhematologic toxicity, except nausea,
vomiting, and diarrhea, in the absence of optimal sup-
portive therapy; hyperglycemia temporally related to
corticosteroid prophylaxis; or tolerable skin rash;
Y Inability to receive the full intravenous administration of
paclitaxel-carboplatin and at least 12 doses of CI-1033
(without dose reduction) in the first 15 days of the cycle
due to a treatment-related toxicity;
Y Inability to begin a subsequent treatment cycle within 14
days of the scheduled start date due to any treatment-
related toxicity.
MTD was defined as the highest dose of CI-1033, in
combination with paclitaxel-carboplatin that resulted in
33% of subjects in a six-subject cohort experiencing a
treatment-related DLT within the first cycle.
Pretreatment evaluation included a history and physical
examination with documentation of concomitant medica-
tions, ECOG PS, complete blood count, differential and
platelet count, serum chemistries, coagulation profile, and
urinalysis. Women of childbearing potential had a serum or
urine pregnancy test. In addition, imaging of the chest, with
baseline tumor measurements, head scan (computed tomog-
raphy or magnetic resonance imaging), and electrocardiogra-
phy were also performed. Follow-up assessments included
physical examination, PS, blood counts, and serum chemis-
tries before each cycle and imaging of the chest (and other
target lesions) for efficacy assessment (every third chemo-
therapy cycle, 9-week intervals).
Treatment Plan
CI-1033 was supplied by Pfizer Global Research and
Development (Ann Arbor, MI) as 5-, 25-, and 75-mg gelatin
capsules. Paclitaxel and carboplatin were commercially avail-
able. Study medications were administered as follows: (1) On
day 1 of each cycle, and following standard premedications
for hypersensitivity and emesis, paclitaxel was dosed at 225
mg/m2 as a 3-hour intravenous infusion. Carboplatin was
dosed to a target area under the concentration curve of 6
mg  min/ml as a 30-minute intravenous infusion immedi-
ately after paclitaxel. (2) CI-1033 was administered daily as
a single oral dose, starting on day 2 of each cycle, for 14
consecutive days.
The CI-1033 schedule was selected based on preclinical
and clinical data indicating a schedule-dependent additive
effect after chemotherapy21,22 and continued pharmacody-
namic activity (suppressed tumor EGFR phosphorylation 1
week after therapy) despite weekly drug rest periods, respec-
tively.26 The CI-1033 starting dose of 50 mg/day was selected
based on preclinical single-agent toxicity and safety data and
phase I biomarker modulation data that indicated EGFR
inhibition at the 50-mg dose level.23,24 CI-1033 dosing was
increased in 100% increments (50, 100, 200 mg). The dose
of CI-1033 was not increased in individual patients, and
chemotherapy dose adjustments were allowed as a result of
changes in serum creatinine or body weight.
Three assessable patients were treated in each cohort. If
no DLTs (first cycle only) were observed, then additional
patients were entered at the next dose level. If one DLT was
observed, the cohort was expanded to include six patients. If
more than one patient experienced a DLT, enrollment into
that cohort ceased and the next cohort combined the same
doses of paclitaxel-carboplatin with a 50-mg reduction in the
CI-1033 dose. On determination of the MTD, the RP2D
cohort was expanded to 22 subjects to further define safety
and antitumor activity.
Combination treatments were repeated every 21 days,
for a total of four to six cycles, contingent on the return of all
treatment-related AEs (except tolerable skin rash or alopecia)
to grade 1 or baseline levels. Patients completing at least
four cycles of therapy with no evidence of disease progres-
sion (PD) or intolerable toxicity were eligible to continue on
treatment with single-agent CI-1033 as a continuous daily
dose. Patients with a complete response (CR), partial re-
sponse (PR), or stable disease (SD) continued assessments
every 2 months until PD, death, initiation of new anticancer
therapy, withdrawal, or loss to follow-up. All patients were
followed for a minimum of 30 days after the last dose of
CI-1033.
Toxicity Criteria and Dose Modifications
All toxicities were graded according to the National
Cancer Institute Common Toxicity Criteria version 2.0 guide-
lines. Treatment interruptions and dose reductions were based
on hematologic and nonhematologic toxicities. In the case of
grade 3 and 4 toxicity, dose reductions were based on the
assumption of drug causality and were done using predeter-
mined criteria (20% and 25% for paclitaxel and carboplatin,
respectively, previous dose level for CI-1033). Subsequent
dose increase was not permitted.
Pharmacokinetics
Patients underwent pK profiling for paclitaxel (24
hours) on day 1 of the first two cycles as well as for CI-1033
(8 hours) on day 15 of the first cycle. Plasma samples for
CI-1033 were collected before dosing and at 2, 4, 6, and 8
hours after dosing. Plasma samples for paclitaxel were col-
lected before infusion and 1.5, 3, 3.25, 3.5, 4.5, 8.5, and 24
hours after starting the infusion. Plasma paclitaxel concen-
tration-time profiles were analyzed using standard noncom-
partmental methods. Derived parameters included area under
the concentration curve, Cmax, and clearance. CI-1033 sys-
temic exposure was compared to previous experience through
simulation using a previously derived population pK model
and doses and sample times used in this study.27
Plasma samples were stored at 20°C before assay.
CI-1033 was isolated from a 0.2-ml aliquot of plasma using
an acetonitrile protein precipitation reaction. Paclitaxel was
isolated through solid-phase extraction. All quantizations
were done by liquid chromatography and mass spectroscopy.
The resulting ranges of quantization for CI-1033 and pacli-
taxel were 1.0 to 500 ng/ml and 5.00 to 1000 ng/ml, respec-
tively. Overall precisions, expressed as the relative SD
(%CV) of quality control samples averaged 9.9% and 5.6%
with overall accuracies, expressed as the percentage of rela-
tive error (%RE), ranged from 7.7% to 1.6% and 1.0% to
6.9% for CI-1033 and paclitaxel, respectively.
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Efficacy and Biomarker Assessment
Tumor response was assessed according to the Re-
sponse Evaluation Criteria in Solid Tumors.28 Before enroll-
ment, tumor samples were tested for the expression of all
erb-B receptors (erb-B 1 to 4). A centralized laboratory
(IMPATH Inc, Los Angeles, CA) performed IHC staining
and analysis on formalin-fixed, paraffin-embedded material.
Expression was assessed using a standard semiquantitative
scale that scored staining as 0 (absent staining), 1 (slight
staining in 10% cells), 2 (moderate staining in 10% of
cells), or 3 (marked staining in 10% of cells). The
H-score method29 was also used to demonstrate expression
and was calculated based on the total number of cells stained
at each intensity.
Statistical Considerations
Planned enrollment in each dose cohort was three to six
patients based on the observed safety profile. The purpose of
the enlarged sample size at the RP2D was to characterize
more precisely the safety (and report any observed efficacy)
of that dose. Although the total size of this expanded cohort
was not selected according to a specific statistical test, based
on the binomial distribution, for any grade 3 or 4 AE that had
a true incidence of 10%, a target sample size of 22 patients
yielded a 90% probability of observing at least one occur-
rence of that AE.
Descriptive statistics were used to summarize all pK
parameters as well as safety and efficacy endpoints (mean,
SD, CV, and minimum, maximum, and median values). The
ORR is provided with an exact two-sided 95% confidence
interval, using standard methods based on the binomial dis-
tribution. Kaplan-Meier30 estimates of the PFS and OS curves
are presented. Median event times with two-sided 95% con-
fidence intervals are provided using normal approximation.
The 1-year PFS and OS rates, with two-sided 95% confidence
intervals were calculated from the Kaplan-Meier curve.
RESULTS
Patient Characteristics
Between February of 2003 and March of 2004, a total
of 39 patients were enrolled in this study. Each patient
received at least one cycle of chemotherapy plus one dose of
the study drug. All patients were assessable for toxicity.
Patient demographics are shown in Table 1. Sixty-two per-
cent of patients were male and the median age was 61 years
(range, 28–79). Only 31% of patients had ECOG PS 0 and
the most frequent histology was adenocarcinoma (22 patients
or 56.4%). Four patients with locally advanced disease (stage
IIIB) were included.
Dose Escalation, DLTs, and MTD
Four dose cohorts of CI-1033 were examined; 50 mg
(three patients), 100 mg (four patients), 150 mg (seven
patients), and 200 mg (six patients). No DLTs were reported
in the 50- or 100- mg cohorts, and CI-1033 was increased to
100 and 200 mg (100%), respectively. At the 200-mg dose
level, two DLTs were observed in six patients (acneiform
rash and diarrhea). Accordingly, the CI-1033 dose was de-
creased by 50 mg. Three patients reported DLTs at the
150-mg dose level (n  7) including acneiform rash, asthe-
nia, and hypotension. The MTD for CI-1033 (oral, days
2–15) in combination with paclitaxel-carboplatin was estab-
lished at 100 mg, and an additional 19 patients were enrolled
in this cohort (RP2D cohort) to further define its safety and
antitumor activity.
TABLE 1. Patient Demographics and Disease Characteristics
Patients
Characteristic No. %
Total population 39 100
Age (yr)
Median (range) 61 (28–79)
70 29 74.4
70 10 25.6
Gender
Male 24 61.5
Female 15 38.5
Race
White 37 94.9
Black 1 2.6
Asian or Pacific Islander 1 2.6
ECOG PS
0 12 30.8
1 27 69.2
Stage
III B (MPE) 7 17.9
IV 31 78.4
N/A 1 2.5
Histology
Adenocarcinoma 22 56.4
Squamous 12 30.7
Large 2 5.1
NSCLC 1 2.5
N/A 2 5.1
Previous therapy
None 28 71.7
Surgery 6 15.3
Radiation 5 12.8
Positive receptors
N/A 1 2.5
2 7 17.9
3 17 43.5
All (4) 14 35.8
Receptor IHC
N/A 4
0 32
1 24
2 27
3 69
ECOG PS, Eastern Cooperative Oncology Group performance status; MPE, ma-
lignant pleural effusion; NSCLC, non-small cell lung cancer; N/A, not available; IHC,
immunohistochemistry.
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Treatment Status and Patient Disposition
All 39 patients received at least one cycle of chemo-
therapy plus CI-1033. Treatment details are summarized in
Table 2. A total of 153 cycles of chemotherapy were admin-
istered. The median number of cycles was four, with 21
patients receiving four or more cycles (18 and 15 patients
received five and six cycles, respectively). Twenty-one pa-
tients withdrew from the study before starting single-agent
CI-1033 (10 PD, one refusal, 10 AEs). No patient in the
50-mg cohort discontinued therapy due to an AE. In the
100-mg cohort, four subjects discontinued therapy due to an
AE (treatment-related nausea/vomiting and weight loss). In
the 150-mg cohort, three patients discontinued therapy due to
an AE (acne, asthenia, diarrhea), and all of them were
considered treatment related. Three patients in the 200-mg
cohort 4 discontinued therapy due to an AE (nausea/vomit-
ing, acne/rash, and asthenia). All were treatment related. Only
six patients required paclitaxel and/or carboplatin dose reduc-
tions, and multiple dose reductions were not necessary.
Eighteen patients were eligible to receive single-agent
CI-1033. The median duration of single-agent CI-1033 use
was six cycles (range, one to 22). At the time of this analysis,
six patients continued on single-agent CI-1033 and 12 pa-
tients had been removed from study (two withdrew due to
AEs, nine developed PD, and one refused therapy).
Safety and Toxicity
Treatment-related AEs were reported by 36 of the 39
study subjects (92.3%, Table 3). The most frequent AEs were
gastrointestinal and dermatologic, including diarrhea, nausea,
acne, stomatitis, rash, and vomiting. In addition, asthenia,
alopecia, anorexia, peripheral neuropathy, leucopenia, and
myalgias/arthralgias also occurred in 20% of subjects,
probably reflecting the use of conventional chemotherapy.
The incidence of gastrointestinal and constitutional symp-
toms appeared to increase with CI-1033 doses, whereas it
seemed relatively dose independent with hematologic and
skin-related AEs. Treatment-related AEs were reported by 20
of 23 subjects (87.0%) in the 100-mg cohort. The distribution
of AEs reported by 20% of subjects in this cohort was very
similar to that of the entire study population (Table 3).
The principal AEs at all dose levels were mostly grade
1 or 2 (Table 4). The most common grade 3 or 4 AE was
leukopenia, amounting to 28% of the patients. Only one case
of febrile neutropenia was observed. Grade 3 to 4 AEs
occurred with higher frequencies with increasing doses of
CI-1033. In the 100-mg cohort, there were five patients with
leukopenia, three with anemia, two with peripheral neuropa-
thy, and one with diarrhea, nausea, and vomiting. The inci-
dence of these toxicities was not different with higher CI-
1033 doses than for the 100-mg CI-1033 dose (Table 4).
TABLE 2. Treatment Status and Patient Disposition
Paclitaxel  Carboplatin Plus CI-1033
50-mg Cohort* 100-mg Cohort† 150-mg Cohort 200-mg Cohort Total
No. % No. % No. % No. % No. %
Entered combination treatment 3 100 23 100 7 100 6 100 39 100
No. of treatment cycles
Total 15 90 24 24 153
Median 6 4 2 3.5 4
Range 3–6 1–6 1–6 1–6 1–6
4 1 33.3 10 43.5 4 57.1 3 50.0 18 46.2
4 2 66.7 13 56.5 3 42.9 3 50.0 21 53.8
Completed chemotherapy‡ 2 66.7 11 47.8 2 28.6 3 50.0 18 46.2
Withdrew during treatment† 1 33.3 12 52.2 5 71.4 3 50.0 21 53.8
Progression of disease 1 33.3 7 30.4 2 28.6 0 10 25.6
Adverse event 0 4 17.4 3 13.0 3 50.0 10 25.6
Refused 0 1 4.3 0 0 1 2.6
Entered single-agent treatment 2 66.7 11 47.8 2 28.6 3 50.0 18 46.2
Withdrew during treatment 1 33.3 7 30.4 1 14.3 3 50.0 12 30.7
Progression of disease 0 6 26.1 1 14.3 2 33.3 9 23.1
Adverse event 0 1 4.3 0 1 16.7 2 5.1
Other* 1 33.3 0 0 0 1 2.6
No. of treatment cycles
Median 6
Range 1–22
*One patient withdrew for other reasons in the single-agent part.
†One patient refused in the combination part.
‡One and two patients from the 150- and 100-mg cohorts, respectively, did not receive single-agent CI-1033 due to progression of disease or adverse event after completing four
or more cycles of combination therapy.
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At the time of this analysis, 13 of 39 subjects (33.3%)
had died; none in the 50-mg CI-1033 cohort, seven (30.4%)
in the 100-mg CI-1033 cohort, four (57.1%) in the 150-mg
CI-1033 cohort, and two (33.3%) in the 200-mg CI-1033
cohort. The majority of deaths were due to PD, and none were
considered study drug related.
Pharmacokinetics
PK profiles were obtained in all 18 patients for CI-1033
(cycle 1, day 15) and in 19 and 13 patients for paclitaxel in
cycles 1 and 2, respectively. Consistent with previous expe-
rience, CI-1033 plasma concentrations were highly variable
with relative SDs ranging from 48% to 81% for the 23
patients in the 100-mg cohort (Table 5). Day 15 CI-1033
mean predose (trough) concentrations ranged from 2.9 to 11.7
ng/ml across all cohorts with no clear dose dependence. Except
for the 150-mg cohort, mean peak plasma CI-1033 concentra-
tions increased with dose and were achieved 2 to 4 hours after
dosing. Mean CI-1033 concentration at each time point for each
dose was compared to the corresponding simulated value ob-
tained using a previously determined population pK model of
CI-1033 disposition. On average, CI-1033 plasma concentra-
tions were approximately 50% higher than expected, but with a
relative SD of 47%, this higher sample mean was not statistically
significant (data not shown).
Mean plasma paclitaxel concentrations for cycles 1 and 2
are shown in Figure 1. Peak paclitaxel concentrations averaged
TABLE 3. Frequency of the Most Common Associated Adverse Events During the Study
50-mg Cohort
(n  3)
100-mg Cohort
(n  23)
150-mg Cohort
(n  7)
200-mg Cohort
(n  6)
Total
(n  39)
Adverse Event No. % No. % No. % No. % No. %
Diarrhea 2 66.7 16 69.6 6 85.7 6 100.0 30 76.9
Stomatitis 2 66.7 17 73.9 3 42.9 6 100.0 28 71.8
Nausea 2 66.7 15 65.2 5 71.4 5 83.3 27 69.2
Asthenia 2 66.7 13 56.5 5 71.4 5 83.3 25 64.1
Alopecia 1 33.3 13 56.5 4 57.1 6 100.0 24 61.5
Acne 2 66.7 10 43.5 4 57.1 4 66.7 20 51.3
Peripheral neuropathy 2 66.7 9 39.1 5 71.4 4 66.7 20 51.3
Vomiting 1 33.3 10 43.5 5 71.4 2 33.3 18 46.2
Rash 2 66.7 10 43.5 0 0.0 4 66.7 16 41.0
Anorexia 0 0.0 7 30.4 2 28.6 5 83.3 14 35.9
Leukopenia 2 66.7 5 21.7 3 42.9 1 16.7 11 28.2
Anemia 1 33.3 7 30.4 2 28.6 0 0.0 10 25.6
Dyspepsia 1 33.3 6 26.1 2 28.6 1 16.7 10 25.6
Myalgia/arthralgia 0 0.0 6 26.1 1 14.3 3 50.0 10 25.6
Pruritus 1 33.3 3 13.0 1 14.3 2 33.3 7 17.9
Epistaxis 1 33.3 4 17.4 1 14.3 0 0.0 6 15.4
Weight loss 0 0.0 4 17.4 0 0.0 2 33.3 6 15.4
Dry skin 1 33.3 3 13.0 1 14.3 0 0.0 5 12.8
Dehydration 0 0.0 1 4.3 2 28.6 1 16.7 4 10.3
Fever 0 0.0 2 8.7 1 14.3 1 16.7 4 10.3
Infection 0 0.0 2 8.7 2 28.6 0 0.0 4 10.3
Adverse events occurring with 10% frequency in combined dose groups.
TABLE 4. Principal Paclitaxel-carboplatin Plus CI-1033–related Toxicities by Adverse Event Intensity*
Diarrhea
Grade
Nausea
Grade
Acne
Grade
Stomatitis
Grade
Vomiting
Grade
P. neuro.
Grade
Rash
Grade
Leukopenia
Grade
Anemia
Grade
Dose (mg) No. 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
50 3 2 0 2 0 2 0 2 0 1 0 2 0 2 0 0 2 1 0
100 23 15 1 14 1 10 0 17 0 9 1 7 2 10 0 0 5 4 3
150 7 4 2 5 0 3 1 3 0 5 0 5 0 0 0 0 3 1 1
200 6 5 1 4 1 3 1 6 0 1 1 2 2 4 0 0 1 0 0
Total 39 26 4 25 2 18 2 28 0 16 2 16 4 16 0 0 11 6 4
*Maximum intensity per patient.
P. neuro., Peripheral neuropathy
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8.1 and 7.5 ng/ml and paclitaxel clearances averaged 8.3 and 8.4
liter/hr/m2 for the same cycles, respectively. These values are
well within the range anticipated by the literature and suggest
no effect of CI-1033 (once daily for 14 days) on paclitaxel
administration given 6 days later (Figure 2A). This was
corroborated further by data collected from the 13 patients
receiving both courses of treatment (Figure 2B).
Efficacy and Biomarker Results
No CRs were observed. Ten (25.6%) subjects achieved
a PR and eleven (28.8%) SD; one each at the 50-mg level, six
each at the 100-mg level, one PR, and two SDs at the 150-mg
level, and two each at the 200-mg level. The ORR was 25.6%
(30% for patients at the RP2D). The median PFS was 5.1
months with a mean survival time of 12.4 months and 1- and
2-year survival rates of 50% and 34%, respectively (Figure 3).
Tumor biopsy samples were available for all patients,
but data on one patient was missing post-study. Seven pa-
tients expressed one or two receptors, 17 expressed three
receptors, and 14 expressed all four receptors (Table 1). The
frequency of receptor overexpression was as follows: erb-B 1
86.8%, erb-B 2  18.4%, erb-B 3  92.1%, and erb-B 4 
55.3%. The limited number of patients in this study precluded
any attempts to correlate these findings with any of the study’s
secondary endpoints.
DISCUSSION
Important mechanisms of aberrant EGFR activation in
NSCLC include receptor overexpression, gene amplification,
and activating mutations.31 EGFR dimerizations with other
erb-B receptors result in variable signaling potencies highly
dependent on the levels of the dimerizing coreceptors (dimer
relative potency: EGFR/EGFR  3.2, EGFR/HER-2  5.0,
EGFR/erb-B 3  6.5 and HER-2/erb-B 3  10.5).32 These
potent non-EGFR–containing dimers highlight potential
mechanisms of resistance against reversible, selective (EGFR
only) TKIs. The inability to overcome acquired mechanisms
of resistance such as EGFR secondary mutations33 or in-
creased internalization of the activated EGFR (altered recep-
tor trafficking)31 may limit the efficacy of this class of agents.
Therefore, agents with adenosine triphosphate–blocking ac-
TABLE 5. CI-1033 Systemic Exposure (ng/ml) on Day 15 After 14 Days of Once-daily Dosing in Cycle 1
Dose mg
(n)
50 mg
(n  3)
100 mg
(n  7)
150 mg
(n  4)
200 mg
(n  4)
Time (hrs post dose) Mean % RSD Mean % RSD Mean % RSD Mean % RSD
0 6.3 73 11.7 81 2.9 76 6.9 52
2 33.4 43 95.1 49 41.7 82 139.5 52
4 38.4 13 108.1 62 67.9 69 138.5 86
6 37.3 1 77.2 64 58 79 111.9 77
8 24.97 38 50.9 48 37.9 79 87.8 76
RSD, relative SD.
FIGURE 1. Day 1 mean plasma paclitaxel concentration-time distribution.
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tivities extending to all the erb-B receptors (pan–erb-B TKIs)
that cannot be reversed (irreversible) by other resistance
mechanisms may be better suited for downstream blockade of
(EGFR- and non-EGFR–containing) erb-B receptor dimer–
triggered signaling.
The novel TKI CI-1033 represents an excellent choice
for this enterprise. However, because of its theoretical ability
(as irreversible, pan-erb B receptor TKIs) to achieve a longer
in situ half-life at its molecular target, potentially generating
increased efficacy15,34 (and also enhanced toxicity), further
investigation of this drug, particularly when used in combi-
nation with other cytotoxic agents such as paclitaxel-carbo-
platin, is a necessity. In this phase I study, we identified an
MTD and characterized the toxicity profile for the combina-
tion of CI-1033, given in a putatively additive schedule (after
chemotherapy), with standard paclitaxel-carboplatin as first-
line therapy for patients with advanced NSCLC and any
possible pK interactions between CI-1033 and paclitaxel. In
addition, although strictly speaking, this was not a phase II
study, 36 of 39 patients were treated with doses of CI-1033 at
or above the RP2D, enabling an estimate of efficacy param-
eters for the combination of carboplatin, paclitaxel, and
CI-1033.
Other EGFR TKIs in combination with chemotherapy
have been previously tested and ample data regarding their
tolerability and AEs are available.24 In those trials, most of
the AEs reported occurred during combination treatment and
many were attributable to chemotherapy, with the exception
of rash or acne and diarrhea, which are known to be associ-
ated with EGFR TK inhibition. For most of the toxicities in
question, the frequencies observed in our study were similar
to those of other trials of EGFR TKIs in combination with
paclitaxel-carboplatin. Exceptions worthy of mentioning are
higher incidences of stomatitis and peripheral neuropathy and
a lower incidence of rash. Several studies using single-agent
CI-1033 have consistently reported other toxicities, such as
nausea/vomiting, asthenia, and anorexia. Given the high fre-
quencies reported for these toxicities in single-agent CI-1033
studies, it is not difficult to explain such similarly high
incidences in our combination trial. The incidences of periph-
eral neuropathy and leukopenia in our study, however, con-
trast with much lower incidences for similar toxicities in
combination trials with gefitinib or erlotinib. Whether this is
a reflection of a small sample size, patient selection, an
“augmented” cytotoxic effect of chemotherapy due to the
CI-1033 schedule used, or the direct inhibitory effect of the
pan–erb-B TKI cannot be determined from the available
information.
In a previous phase I dose escalation study with CI-
1033, administered on a similar dosing schedule to that used
in the current study, the MTD for single-agent CI-1033 was
determined to be 450 mg.35 In the current study, however, the
MTD dropped to 100 mg, suggesting a potential pharmaco-
logic interaction between CI-1033 and the cytotoxic agents.
Because both paclitaxel and CI-1033 are metabolized, at least
in part, by cytochrome P-450 isoform 3A4, we explored
whether coadministration of these drugs could result in a
significant effect on the exposure to paclitaxel or the steady
state of CI-1033 or both. Because carboplatin is excreted
unchanged by the kidneys, an interaction with CI-1033 was
FIGURE 2. Paclitaxel clearance (liter/hr/m2) before (cycle 1) (A) and after 14 days of once-daily CI-2033 dosing (cycle 2) (B).
FIGURE 3. Kaplan-Meier progression-free and overall
survival curves.
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not anticipated and carboplatin pK was not evaluated. We
found no evidence of any CI-1033 effect on the exposure to
paclitaxel, results consistent with those of studies of other
EGFR TKIs.15,34 This suggests that the decrease in CI-1033
dose required is unrelated to the drug schedule used, unlikely
to compromise the cytotoxic activity of the combination, but
may be related to the pan–erb-B receptor inhibitory capacity
of CI-1033 not observed with the traditional EGFR-only
TKIs. Another possibility is that there are non-pK interac-
tions resulting in enhanced toxicity from the combination of
paclitaxel-carboplatin and CI-1033 than would be expected
from the agents individually.
In terms of antitumor activity, the ORR of 25.6% for
the whole population (30% for the RP2D 100-mg cohort) is
numerically similar to that observed for other chemotherapy–
EGFR TKI combinations (20%–50%)36 and in keeping with
the outcomes of representative phase II platinum doublet
studies including cisplatin or carboplatin plus gemcitabine,
paclitaxel, or docetaxel. Furthermore, the ORR reported is
similar to that obtained by the combination of paclitaxel-
carboplatin plus bevacizumab (a monoclonal antibody against
the vascular endothelial growth factor [VEGF]) which, so far,
is the only platinum doublet plus biologic agent combination
to demonstrate, in a phase III randomized trial, a survival
advantage in untreated, advanced NSCLC.37 Additionally, the
PFS, mean survival time, and 1- and 2-year-survival rate data
obtained in this study compare favorably to those of previous
studies and suggest the potential activity of this regimen in
NSCLC.
In conclusion, this trial confirms the overall safety and
lack of significant pK interactions of CI-1033, an irreversible
pan–erb-B TKI, in combination with paclitaxel-carboplatin
as first-line therapy in advanced NSCLC. The survival sug-
gested by the addition of CI-1033 used in a potentially
synergistic schedule with standard chemotherapy compares
favorably to historical controls, provides an impetus, and
emphasizes the need for further testing and a confirmatory
safety and efficacy phase II study.
ACKNOWLEDGMENTS
The authors thank Meredith Sheeran for her excellent
assistance in the summarization of clinical study data, Eliz-
abeth Zegarac for her organization skills in database man-
agement (Pfizer Inc.), and Rachna Kapoor, MBBS, MPH, for
her assistance with the survival analysis (H. Lee Moffitt
Cancer Center). Anita Bruce, MA, provided editorial assis-
tance (H. Lee Moffitt Cancer Center).
REFERENCES
1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer
J Clin 2005;55:10–30.
2. Barnoya J, Glantz S. Association of the California tobacco control
program with declines in lung cancer incidence. Cancer Causes Control
2004;15:689–695.
3. Buter J, Giaccone G. Medical treatment of non-small-cell lung cancer.
Ann Oncol 2005;16(Suppl 2):ii229–232.
4. Senan S, Lagerwaard FJ. The role of radiotherapy in non-small-cell lung
cancer. Ann Oncol 2005;16(suppl 2):ii223–ii228.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
6. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin
Oncol 2002;20:2881–2894.
7. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part II. J Clin
Oncol 2002;20:3016–3028.
8. Lynch TJ, Adjei AA, Bunn PA, et al. Novel agents in the treatment of
lung cancer: conference summary statement. Clin Cancer Res 2004;10:
4199s–4204s.
9. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment
of non-small-cell lung cancer. J Clin Oncol 2005;23:3235–3242.
10. Giaccone G. HER1/EGFR-targeted agents: predicting the future for
patients with unpredictable outcomes to therapy. Ann Oncol 2005;16:
538–548.
11. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer
Res 2004;10:4233s–4237s.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
13. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J
Cancer 2001;4(37 suppl):S9–S15.
14. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal
growth factor receptor and in KRAS are predictive and prognostic
indicators in patients with non-small-cell lung cancer treated with
chemotherapy alone and in combination with erlotinib. J Clin Oncol
2005;23:5900–5909.
15. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a
phase III trial–INTACT 2. J Clin Oncol 2004;22:785–794.
16. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of
erlotinib hydrochloride (OSI-774) combined with carboplatin and pac-
litaxel chemotherapy in advanced non-small-cell lung cancer. J Clin
Oncol 2005;23:5892–5899.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med 2005;353:
123–132.
18. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care
in previously treated patients with refractory advanced non-small-cell
lung cancer: results from a randomised, placebo-controlled, multicentre
study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:
1527–1537.
19. Klohs WD, Fry DW, Kraker AJ. Inhibitors of tyrosine kinase. Curr Opin
Oncol 1997;9:562–568.
20. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine
kinase inhibitor. Semin Oncol 2001;28:80–85.
21. CI-1033 Investigator’s Brochure. Pfizer Global Research and Develop-
ment. 2003.
22. Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to
promote apoptosis in response to ErbB receptor family inhibition. J Biol
Chem 2001;276:14842–14847.
23. Calvo E, Tolcher AW, Hammond LA, et al. Administration of CI-1033,
an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day
on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Clin Cancer Res 2004;10:7112–7120.
24. Nemunaitis J, Eiseman I, Cunningham C, et al. Phase 1 clinical and
pharmacokinetics evaluation of oral CI-1033 in patients with refractory
cancer. Clin Cancer Res 2005;11:3846–3853.
25. Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase
II trial of oral CI-1033 for previously treated advanced ovarian cancer.
J Clin Oncol 2005;23:5597–5604.
26. Allen LF, Lenehan PF, Eiseman IA, et al. Potential benefits of the
irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast
cancer. Semin Oncol 2002;29:11–21.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organiza-
tion for Research and Treatment of Cancer, National Cancer Institute of
the United States, National Cancer Institute of Canada. J Natl Cancer
Inst 2000;92:205–216.
28. Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for
immunohistochemical semiquantitation: validation for oestrogen recep-
tor in breast carcinomas. J Clin Pathol 1995;48:876–878.
29. Kaplan E, Meier P. Nonparametric estimation for incomplete observa-
tions. J Am Stat Assoc 1958;53:457–481.
Chiappori et al. Journal of Thoracic Oncology • Volume 1, Number 9, November 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer1018
30. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal
growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445–
2459.
31. Arteaga CL: The epidermal growth factor receptor: from mutant onco-
gene in nonhuman cancers to therapeutic target in human neoplasia.
J Clin Oncol 2001;19:32S–40S.
32. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung
adenocarcinomas to gefitinib or erlotinib is associated with a second
mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
33. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad
Sci U S A 2005;102:7665–7670.
34. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of
erlotinib hydrochloride (OSI-774) combined with carboplatin and
paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin
Oncol 2005;23:5892–5899.
35. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin
and paclitaxel in patients with stage IIIB or IV non-small-cell lung
cancer. J Clin Oncol 2003;21:2094–2100.
36. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pem-
etrexed in combination with carboplatin in the first-line treatment of
advanced nonsmall cell lung cancer. Cancer 2005;104:2449–2456.
37. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of
paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #
704865) in patients with advanced non-squamous non-small cell lung
cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG)
Trial-E4599. Proc Am Soc Clin Oncol 2005;23:(LBA 4).
Journal of Thoracic Oncology • Volume 1, Number 9, November 2006 CI-1033 Plus Paclitaxel-Carboplatin in Advanced NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 1019
